nuovi laboratori controllo qualità e ricerca & sviluppo ...· nuovi laboratori controllo qualità

Download Nuovi laboratori Controllo Qualità e Ricerca & Sviluppo ...· Nuovi laboratori Controllo Qualità

Post on 17-Feb-2019

212 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

Nuovi laboratori Controllo Qualit e Ricerca & Sviluppo

Posa della prima pietra

26 febbraio 2015

Bogdan Oghina

Enrico Cozzi

Carlos Villalobos

Antonella Martignoni

Vera Terragni

Lorena Muggetti

Claudio Zaninetti

Managing Director, Injectables

Major of Nerviano

VP, Injectables and Biologics

Executive Director, Quality Injectables/Biosimilars

Quality Operations Director

Research & Development Director

Engineering, Maintenance & Utilities Director

I relatori

Actavis

Actavis (NYSE:ACT) markets a broad portfolio of branded and generic pharmaceuticals and

develops innovative medicines for patients suffering from diseases principally in the Central Nervous

System, Gastroenterology, Womens Health, Urology, Cardiovascular, Respiratory and Anti-infective

therapeutic categories.

The Company is an industry leader in R&D, with one of the broadest brand development pipelines in

the pharmaceutical industry, and a leader in the submission of generic product applications. Actavis

has commercial operations in 60+ countries and operates 30+ manufacturing and distribution

facilities around the world.

3

Actavis by the Numbers

Commercial Operations in 60+ Countries

Markets/Distributes

nearly 1,000 products

30+ manufacturing facilities

20+ R&D centers

~44+ billion unit capacity

25+ specialty brand products

in near or mid-term stage of

development

Our business

Evolution of Actavis 1984 - Today

1984

Expanding Global Generics

2006 - 2012

Emerging Brand and

Specialty Global

Company

2013 - 2014

November 17, 2014

6

Announced November 17, 2014

An Exceptional Transaction Announced November 17, 2014

Creates a New Top 10 Global Growth Pharmaceutical

Company

- $23B of pro forma revenue in 2015

$66B cash and stock deal at $219 per share

Approved by both Boards; strongly supported by both

management teams

- Subject to shareholder approval of both companies; customary

regulatory approvals

- Anticipate the transaction to close in the second quarter of 2015

Industry-leading combined management team led by Brent

Saunders, CEO and President and Paul Bisaro, Executive

Chairman

8

The Most Dynamic Company in Growth Pharma An Exceptional Company by the Numbers

Double-

Digit %

Accretion

10+%

Revenue

Growth

Target

>30,000 Employees

$8B Free Cash

Flow in 2016

~$23B Global

Revenue

~$1.7B R&D Spend

~$147B Enterprise

Value

2017

Aspiration

$25 EPS

9

Creating the Most Dynamic Company in

Growth Pharma

10

$15 Billion Global Brand Portfolio 6 Blockbuster Franchises & Strong Anti-Infectives/Established Brands Franchises

Acta

vis

A

llerg

an

Womens Health

& Urology Ophthalmology CNS

Cardiovascular &

Respiratory

GI &

Cystic Fibrosis

Dermatology &

Aesthetics

~$3 Billion+ ~$3 Billion+ ~$3 Billion+ $1 Billion+ $1 Billion+ $1 Billion+

Anti-infectives &

Est. Brands

http://www.google.com/url?url=http://www.frx.com/Products&rct=j&frm=1&q=&esrc=s&sa=U&ei=awJbVKLQM4iVyQTskYLYDA&ved=0CBgQ9QEwAQ&usg=AFQjCNGbappa2IUvamsCDaV-Qsi42WeV0whttp://www.google.com/url?url=http://www.practiceofmadness.com/2013/11/medical-advertising-images/&rct=j&frm=1&q=&esrc=s&sa=U&ei=xgNbVOijMderyAST_IK4CQ&ved=0CBYQ9QEwAA&usg=AFQjCNH9im1Bjg148vYxO_O7_toMpul1Awhttp://www.google.com/url?url=http://medcitynews.com/2009/10/schering-plough-launches-schizophrenia-bi-polar-disorder-drug-after-buying-maker/saphris-logo/&rct=j&frm=1&q=&esrc=s&sa=U&ei=S_ZgVOzqLoi5yQTehoGwCg&ved=0CBYQ9QEwAA&usg=AFQjCNGjGX--prdebKOrX7ztB_9-DHTTqwhttp://www.google.com/url?url=http://www.frx.com/Products&rct=j&frm=1&q=&esrc=s&sa=U&ei=OgNbVOTzKpS0yATr9oLQDQ&ved=0CBoQ9QEwAg&usg=AFQjCNG5uN2Fw1rzkQqY3a_1_MCnrht7Gwhttp://www.google.com/url?url=http://www.tudorzahcp.com/&rct=j&frm=1&q=&esrc=s&sa=U&ei=ufdgVIfoGZOVyATd34D4DA&ved=0CBYQ9QEwAA&usg=AFQjCNHSgwjCHlXnpstCYLiGmtmkmsj2PQhttp://www.google.com/url?url=http://www.daliresp.com/&rct=j&frm=1&q=&esrc=s&sa=U&ei=1_dgVN_wIcueyAS-voKABw&ved=0CBgQ9QEwAA&usg=AFQjCNH69-cEr0ZPJLLIJDUi8x5dOtdrhQhttp://www.google.com/url?url=http://thuocthang.vn/tin-tuc/thong-tin-duoc/linzess-thuoc-moi-dieu-tri-hoi-chung-ruot-kich-thich-va-tao-bon/269.aspx&rct=j&frm=1&q=&esrc=s&sa=U&ei=DgNbVMelOZKjyAShk4LgDg&ved=0CBoQ9QEwAg&usg=AFQjCNEIod1CmfmJRTNt4SVOBlBtAqbEWAhttps://www.google.com/url?url=https://www.zenpep.com/&rct=j&frm=1&q=&esrc=s&sa=U&ei=9flgVJOrE8GjyATgvoHADg&ved=0CBYQ9QEwAA&usg=AFQjCNFht523454lGbGePCv_wFHg646UlAhttps://www.google.com/url?url=https://coupondoc.com/coupons/127-lumigan&rct=j&frm=1&q=&esrc=s&sa=U&ei=Icm0U5GTIdSmyATd74HoDA&ved=0CBoQ9QEwAg&usg=AFQjCNFm-_VFBGYIP--ZMhODcTDYxvBSSw

Unparalleled Commercial Reach

Presence in 100 Countries

with Greater Market and

Product Reach A leader in growing

markets including Europe,

Southeast Asia, China, India

and Latin America

World-class commercial sales and marketing organization

competing across multiple market segments Brands, generics, branded-generics, OTC

12

BOTOX CFL Asia

BOTOX Forehead Lines

BOTOX Spasticity Adult LL, Adult UL, Ped LL,

Ped UL

RESTASIS EU

Bimatoprost SR

DARPin AMD

SEMPRANA Headache

LATISSE Brow

Oxymetazoline Rosacea

ACZONE X

SER-120

OZURDEX RVO China

LASTACAFT Japan

Bystolic + valsartan

Namenda + donepezil

Levonorgestrel-releasing intrauterine system

(LNG20)

CAZ-AVI

Viibryd Low- Dose

Eluxadoline

Cariprazine

Esmya

Sarecylcline

Industry-leading Generics Pipeline

60+ First to Files, 228 pending ANDAs

1,200+ Pending MAAs Internationally

Actavis Brands Allergan

~$1.7 Billion Commitment to R&D

Strong Late Stage Pipeline

Actavis Generics

Committed to ~$1.7 Billion Combined R&D Investment

Industry-leading Global Supply Chain

Actavis Injectable Business

Global Injectables Business is Supplied

from two European Facilities

Bucharest (Sindan), Romania:

Role

The origin of the Actavis oncology

business

Small, flexible, niche

Production capabilities:

Cytotoxic freeze-dried and solution

products in vials; SOD (tablets and

capsules)

Annual production volume: ~3M vials & 30M

tab/cps

Approximately 250 employees

Nerviano, Italy:

Role

Delivering scale and capacity

Long history of global supply (formerly a

Pfizer facility)

Production Capabilities:

Containment, Cytotoxic and non-

Cytotoxic freeze-dried and Solution

products in Vials, Amps and Pre-Filled

Syringes

Annual production volume: >25-35 million

vials depending on product mix

Approximately about 450 employees

Diversifying US Generic Portfolio into Alternate Dosage Forms

Other

Hormones

Buccal Transdermal

Oral Liquid

Ophthalmic & Optic

Injectable

Topical

MR Oral Solid

IR Oral Solid

Inhalation

In Market Filed at FDA

In Development

Chart: % of development projects based on # of products in each dosage form

18

Firm believe in excellence and commitment to quality

Increased R&D capabilities

Vital to be competitive in price and supply of our medicines

Engagement and cooperation with our employees, unions, suppliers and

business partners

Video

19

Why invest in Italy, when our competitors invest elsewhere?

20

Actavis Nerviano

21

Actavis Italy SpA

Via L. Pasteur, 10 20014 Nerviano (MI) - Italy

About Nerviano

Nerviano La storia

1969: Farmitalia costruisce lo stabilimento di Nerviano, dedicato alluso veterinario

1975: Farmitalia trasferisce la produzione delle antracicline

1980: Farmitalia acquisisce Carlo Erba e forma Farmitalia Carlo Erba (FICE)

1982: FICE sposta la produzione di tutti gli iniettabili e di tutte le attivit R&D a Nerviano

1994: Kabi Pharmacia acquisisce FICE e forma Pharmacia

1996: Pharmacia si fonde con Upjohn e nasce Pharmacia & Upjohn

2000: Pharmacia & Upjohn si fonde con Monsanto e nasce Pharmacia

2003: Pfizer acquisisce Pharmacia. Pfizer Italy acquisisce Nerviano

2004: Pfizer Italia vende il Centro Ricerche a NMS

2008: Actavis acquisis